InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases an integration of CYTOCON DB and fIVE DB with Heta. Now Heta format is upgraded to allow direct query to databases from the QSP model code without working with database websites.
CYTOCON DB is an online database of human baseline concentrations of cytokines and cells measured in different tissues of healthy subjects and patients suffering from various pathologies. Heta format developed for QSP models encoding into Excel table was upgraded in such a way to allow results of the query to CYTOCON DB to appear in the QSP model code directly in the section describing species included in the model in form of weighted mean and weighted standard deviations for cells and cytokines concentrations. Moreover, results of the query to fIVE DB now appear in the QSP model code directly in the section describing initialization of model parameters in form of weighted mean and minimal and maximal values of model parameters (kbase, Emax/IC50, EC50/IC50, etc.) fIVE DB is an InSysBio project for in vitro experiments information collection and processing.
Such integration of CYTOCON DB and fIVE DB with Heta enables QSP modelers:
About Heta
The Heta Project is an open-source initiative dedicated to transforming the landscape of pharmacology and systems biology modeling. By developing a unified infrastructure and best practices, we empower researchers and practitioners to create dynamic quantitative models with ease and efficiency. Heta is a software tool for the development of large-scale QSP models and compilation into simulation formats.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
← | November 2023 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
|
5
| ||
6
|
7
|
8
|
9
1.
09 Nov 2023 16:15
IRT webinars. InSysBio ecosystem to speed up and facilitate QSP model development
InSysBio announces the upcoming webinar on Immune Response Template (IRT) on November 21 & 28, 2023 at 8am PST / 11am EST. This webinar aims to demonstrate how to use InSysBio ecosystem and IRT in particular to speed up and facilitate QSP model development.
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
1.
27 Nov 2023 17:45
InSysBio to announce a webinar on CYTOCON organized by ASCPT
InSysBio announces its participation in the upcoming webinar on CYTOCON organized by ASCPT entitled "CYTOCON: The Manually Curated Database of Human In Vivo Cell and Molecule Concentrations" on November 28, 2023, 9AM PT, 12PM ET. This webinar aims to demonstrate key features and application of CYTOCON DB.
|
28
|
29
|
30
|